PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.

Also called NCT01581073

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 476 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01581073
Other papers using this trial's data
  • Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial Clinical journal of the American Society of Nephrology : CJASN, 2020-05-07 DOI, PubMed 32245781, PMC7269223 Not in the PMC Open Access subset.
  • Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial Clinical and experimental nephrology, 2023-09 DOI, PubMed 37289335, PMC10432358 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01581073. Randomized; no masking; primary purpose treatment. Start 2012-02-16 (actual); primary completion 2017-12-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease
Acronym
PREDICT
Condition
Diabetes
Intervention (Drug)
Darbepoetin alfa
Lead sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (class: other)
Collaborator
Showa University School of Medicine (class: not stated)

Record details

Record id
cardio:ct-nct01581073
Content hash
2d2ca93bc4b0d24e949c7b9ab8af85e2976e36e30ea1dff3c4ada06a7a7eb04e